

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

208144Orig1s000

Trade Name: Lumify ophthalmic solution, 0.025%.

Generic or Proper Name: brimonidine tartrate

Sponsor: Bausch + Lomb

Approval Date: December 22, 2017

Indication: Lumify ophthalmic solution is indicated for the relief of redness of the eye due to minor eye irritations.

CENTER FOR DRUG EVALUATION AND RESEARCH

208144Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	X
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

208144Orig1s000

APPROVAL LETTER



NDA 208144

NDA APPROVAL

Bausch + Lomb
Attention: Shaun A. Mbithi
Senior Manager, Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Ms. Mbithi:

Please refer to your New Drug Application (NDA) dated February 27, 2017, received February 27, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lumify (brimonidine tartrate) ophthalmic solution, 0.025%.

This new drug application provides for the use of Lumify (brimonidine tartrate) ophthalmic solution for the relief of redness of the eye due to minor eye irritations.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

We remind you that adequate data have not been submitted to support claims of (b) (4). We also remind you that the Drug Facts labeling states that consumers are to stop use of this product if the consumer's condition worsens or persists for more than three days.

LABELING

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling submitted on December 20, 2017 and must be in the "Drug Facts" format (21 CFR 201.66), where applicable:

Submitted Labeling	Date Submitted
2.5 mL carton – Sample and Trade	December 20, 2017
7.5 mL carton - Sample and Trade	December 20, 2017
2.5 mL container label – Sample and Trade	December 20, 2017
7.5 mL container label – Sample and Trade	December 20, 2017

The FPL should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission "**Final Printed Labeling**

for approved NDA 208144.” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to 4 years because the product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients in this age group and is not likely to be used in a substantial number of pediatric patients in this group.

We note that you have fulfilled the pediatric study requirement for ages 5 to 17 years for this application.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jung Lee, Regulatory Project Manager, at (301) 796-3599.

Sincerely,

{See appended electronic signature page}

Karen Murry Mahoney, MD, FACE
Deputy Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KAREN M MAHONEY
12/22/2017